Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Details (Tables)

v3.24.1.u1
Condensed Consolidated Financial Statements Details (Tables)
3 Months Ended
Mar. 31, 2024
Condensed Consolidated Financial Statement Details  
Schedule of accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

March 31, 

December 31, 

    

2024

    

2023

Accrued incentive compensation

$

397

$

1,203

Accrued legal and accounting fees

674

791

Accrued payroll, severance and retention costs

 

128

 

149

Other accrued liabilities

100

625

Total

$

1,299

$

2,768

Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):

Three Months Ended March 31, 

    

2024

    

2023

Numerator

 

  

 

  

Net loss

$

(8,595)

$

(9,813)

Less: Series A accumulated dividends

 

(530)

 

(530)

Less: Series B accumulated dividends

(838)

(838)

Net loss attributable to common stockholders, basic and diluted

$

(9,963)

(11,181)

 

Denominator

 

 

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

 

11,580

 

11,460

Basic and diluted net loss per share attributable to common stockholders

$

(0.86)

$

(0.98)

Schedule of outstanding securities considered anti-dilutive

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):

Three Months Ended March 31, 

    

2024

    

2023

Convertible preferred stock (as converted)

5,003

5,003

Common stock options

 

1,372

1,548

Warrants for common stock

 

131

6

Total

 

6,506

 

6,557